Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NEOG's Cash to Debt is ranked higher than
81% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. NEOG: No Debt )
NEOG' s 10-Year Cash to Debt Range
Min: 0.15   Max: No Debt
Current: No Debt

Equity to Asset 0.88
NEOG's Equity to Asset is ranked higher than
91% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. NEOG: 0.88 )
NEOG' s 10-Year Equity to Asset Range
Min: 0.72   Max: 0.93
Current: 0.88

0.72
0.93
Interest Coverage No Debt
NEOG's Interest Coverage is ranked higher than
80% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. NEOG: No Debt )
NEOG' s 10-Year Interest Coverage Range
Min: 2.5   Max: 9999.99
Current: No Debt

2.5
9999.99
F-Score: 3
Z-Score: 26.04
M-Score: -2.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.61
NEOG's Operating margin (%) is ranked higher than
93% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. NEOG: 19.61 )
NEOG' s 10-Year Operating margin (%) Range
Min: 4   Max: 20.75
Current: 19.61

4
20.75
Net-margin (%) 13.10
NEOG's Net-margin (%) is ranked higher than
90% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. NEOG: 13.10 )
NEOG' s 10-Year Net-margin (%) Range
Min: -1.6   Max: 13.23
Current: 13.1

-1.6
13.23
ROE (%) 10.53
NEOG's ROE (%) is ranked higher than
81% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. NEOG: 10.53 )
NEOG' s 10-Year ROE (%) Range
Min: -2.25   Max: 12.14
Current: 10.53

-2.25
12.14
ROA (%) 9.36
NEOG's ROA (%) is ranked higher than
89% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. NEOG: 9.36 )
NEOG' s 10-Year ROA (%) Range
Min: -1.74   Max: 10.41
Current: 9.36

-1.74
10.41
ROC (Joel Greenblatt) (%) 40.83
NEOG's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. NEOG: 40.83 )
NEOG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.69   Max: 50.5
Current: 40.83

7.69
50.5
Revenue Growth (%) 11.90
NEOG's Revenue Growth (%) is ranked higher than
84% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. NEOG: 11.90 )
NEOG' s 10-Year Revenue Growth (%) Range
Min: -3   Max: 26.3
Current: 11.9

-3
26.3
EBITDA Growth (%) 13.60
NEOG's EBITDA Growth (%) is ranked higher than
85% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. NEOG: 13.60 )
NEOG' s 10-Year EBITDA Growth (%) Range
Min: 2.6   Max: 40.6
Current: 13.6

2.6
40.6
EPS Growth (%) 13.70
NEOG's EPS Growth (%) is ranked higher than
84% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. NEOG: 13.70 )
NEOG' s 10-Year EPS Growth (%) Range
Min: 4.3   Max: 28.4
Current: 13.7

4.3
28.4
» NEOG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

NEOG Guru Trades in Q1 2013

Mario Gabelli 11,000 sh (unchged)
Ron Baron 216,700 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Manning & Napier Advisors, Inc 183,350 sh (-4.24%)
» More
Q2 2013

NEOG Guru Trades in Q2 2013

Chuck Royce 1,000 sh (New)
Mario Gabelli 11,000 sh (unchged)
Ron Baron 216,700 sh (unchged)
Stanley Druckenmiller Sold Out
Manning & Napier Advisors, Inc 96,880 sh (-47.16%)
» More
Q3 2013

NEOG Guru Trades in Q3 2013

Jim Simons 21,000 sh (New)
Mario Gabelli 11,000 sh (unchged)
Ron Baron 216,700 sh (unchged)
Chuck Royce 1,000 sh (unchged)
Manning & Napier Advisors, Inc 96,070 sh (-0.84%)
» More
Q4 2013

NEOG Guru Trades in Q4 2013

Jim Simons 40,500 sh (+28.57%)
Ron Baron 325,050 sh (unchged)
Mario Gabelli 16,500 sh (unchged)
Chuck Royce Sold Out
Manning & Napier Advisors, Inc 109,440 sh (-24.06%)
» More
» Details

Insider Trades

Latest Guru Trades with NEOG

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-09-30 Sold Out 0.02%$25.29 - $31.87 $ 42.2554%0
George Soros 2012-06-30 New Buy0.02%$24.47 - $30.8 $ 42.2559%25000
George Soros 2011-12-31 Sold Out 0.03%$20.09 - $26.6 $ 42.2578%0
George Soros 2011-06-30 Reduce -20.75%0.01%$25.75 - $29.94 $ 42.2553%47368
George Soros 2011-03-31 New Buy0.03%$23.75 - $28.17 $ 42.2565%59768
Mario Gabelli 2011-03-31 Reduce -90.27%$23.75 - $28.17 $ 42.2565%11000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 55.80
NEOG's P/E(ttm) is ranked lower than
66% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.50 vs. NEOG: 55.80 )
NEOG' s 10-Year P/E(ttm) Range
Min: 20.74   Max: 67.38
Current: 55.8

20.74
67.38
P/B 5.50
NEOG's P/B is ranked lower than
61% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. NEOG: 5.50 )
NEOG' s 10-Year P/B Range
Min: 1.92   Max: 6.51
Current: 5.5

1.92
6.51
P/S 6.60
NEOG's P/S is ranked lower than
63% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. NEOG: 6.60 )
NEOG' s 10-Year P/S Range
Min: 1.96   Max: 8.35
Current: 6.6

1.96
8.35
PFCF 98.40
NEOG's PFCF is ranked lower than
80% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.36 vs. NEOG: 98.40 )
NEOG' s 10-Year PFCF Range
Min: 19.71   Max: 375.61
Current: 98.4

19.71
375.61
EV-to-EBIT 35.70
NEOG's EV-to-EBIT is ranked lower than
67% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. NEOG: 35.70 )
NEOG' s 10-Year EV-to-EBIT Range
Min: 13.4   Max: 43.4
Current: 35.7

13.4
43.4
PEG 3.60
NEOG's PEG is ranked lower than
54% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. NEOG: 3.60 )
NEOG' s 10-Year PEG Range
Min: 0.73   Max: 5.61
Current: 3.6

0.73
5.61
Shiller P/E 69.10
NEOG's Shiller P/E is ranked lower than
67% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. NEOG: 69.10 )
NEOG' s 10-Year Shiller P/E Range
Min: 23.85   Max: 83.39
Current: 69.1

23.85
83.39

Valuation & Return

vs
industry
vs
history
Price/Net Cash 37.10
NEOG's Price/Net Cash is ranked lower than
87% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. NEOG: 37.10 )
NEOG' s 10-Year Price/Net Cash Range
Min: 3.9   Max: 194.8
Current: 37.1

3.9
194.8
Price/Net Current Asset Value 15.40
NEOG's Price/Net Current Asset Value is ranked lower than
69% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. NEOG: 15.40 )
NEOG' s 10-Year Price/Net Current Asset Value Range
Min: 2.55   Max: 53.11
Current: 15.4

2.55
53.11
Price/Tangible Book 8.00
NEOG's Price/Tangible Book is ranked lower than
70% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NEOG: 8.00 )
NEOG' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 9.67
Current: 8

1.6
9.67
Price/DCF (Projected) 3.50
NEOG's Price/DCF (Projected) is ranked lower than
68% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. NEOG: 3.50 )
NEOG' s 10-Year Price/DCF (Projected) Range
Min: 0.99   Max: 4.25
Current: 3.5

0.99
4.25
Price/Median PS Value 1.90
NEOG's Price/Median PS Value is ranked lower than
67% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. NEOG: 1.90 )
NEOG' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 2.25
Current: 1.9

0.36
2.25
Price/Peter Lynch Fair Value 3.90
NEOG's Price/Peter Lynch Fair Value is ranked lower than
67% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. NEOG: 3.90 )
NEOG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.44   Max: 4.87
Current: 3.9

0.44
4.87
Price/Graham Number 4.50
NEOG's Price/Graham Number is ranked lower than
72% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. NEOG: 4.50 )
NEOG' s 10-Year Price/Graham Number Range
Min: 0.91   Max: 5.36
Current: 4.5

0.91
5.36
Earnings Yield (Greenblatt) 2.80
NEOG's Earnings Yield (Greenblatt) is ranked lower than
57% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. NEOG: 2.80 )
NEOG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 7.5
Current: 2.8

2.3
7.5
Forward Rate of Return (Yacktman) 15.34
NEOG's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. NEOG: 15.34 )
NEOG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.3   Max: 34.5
Current: 15.34

6.3
34.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:NG2.Germany
Neogen Corporation was formed as a Michigan corporation in June 1981 and actual operations began in 1982. The Company and subsidiaries develop, manufacture, and market a diverse line of products dedicated to food and animal safety. The Company's food safety segment consists of diagnostic test kits and complementary products sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, drug residues, pesticide residues and general sanitation concerns. These products are marketed by company sales personnel in North America, the United Kingdom and other parts of Europe, Mexico and Brazil and by distributors through the rest of the world. The majority of the tests are disposable, single-use, immunoassay and DNA detection products that rely on the Company's proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. The Company's expanding line of food safety products also includes bioluminescence-based diagnostic technology. It operates in two primary business areas: the Food Safety segment, which develops and markets products for the detection of pathogens, natural toxins, allergens and other unwanted substances in food and feed products; and the Animal Safety segment, which develops and markets products and services dedicated to animal health. The products of food safety segment consist of diagnostic test kits and complementary products marketed to food and feed producers and processors to detect dangerous and/or unintended substances in food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, drug residues, pesticide residues and general sanitation concerns. Animal Safety's NeogenVet product line provides value-added products to the veterinary market. Top NeogenVet products include PanaKare, a digestive aid that serves as a replacement therapy where digestion of protein, carbohydrate and fat is inadequate due to exocrine pancreatic insufficiency; Natural Vitamin E-AD, which aids in the prevention and treatment of vitamin deficiencies in swine, cattle and sheep; and RenaKare, a supplement for potassium deficiency in cats and dogs. It manufactures its products in Lansing, Michigan; Lexington, Kentucky; Randolph, Wisconsin; and Ayr, Scotland. The Company competes on the basis of ease of use, speed, accuracy, and other similar performance characteristics of its products. It is subject to substantial governmental regulation.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide